Abstract:
AIM To investigate the effect of Tongxin Pill on platelet aggregation and cardiac function in patients with ST-segment elevation myocardial infarction (STEMI) treated with drug-coated balloon therapy alone in the postoperative period of Qi deficiency and blood stasis.
METHODS Ninety-two STEMI patients with qi deficiency and blood stasis after drug-coated balloon therapy alone in our hospital from February 2022 to September 2023 were selected for the study. The patients were divided into 2 groups by randomized numerical table method, each with 46 cases. All the patients were treated with simple drug-coated balloon therapy. The control group was treated with conventional antiplatelet and anticoagulation therapy after surgery and the observation group was treated with Tongxin pill on the basis of the treatment of the control group. Clinical efficacy, TCM evidence scores, cardiac function indexes, platelet aggregation, inflammatory factors and adverse reactions were compared between the two groups.
RESULTS The total effective rate in the observation group was 91%, higher than that in the control group, 76% (P<0.05). The TCM evidence scores and BNP levels decreased significantly in both groups after treatment, but the TCM evidence scores in the observation group was lower than those in the control group. LVEF increased in both groups after treatment, but LVEF in the observation group was higher than that in the control group (all P<0.01). Platelet aggregation rate decreased in both groups after treatment, and the platelet aggregation rate in the observation group was lower than that in the control group. Platelet inhibition rate was higher in both groups after treatment, and the platelet inhibition rate in the observation group was higher than that in the control group (all P<0.01). After treatment, the levels of IL-1β, IL-8 and SCD40L decreased in both groups and the levels in the observation group was lower than those in the control group (all P<0.01). A total of 2 cases (4.35%) of adverse reactions occurred in the control group and 3 cases (6.52%) in the observation group, and the difference between the two groups was not statistically significant.
CONCLUSION Tongxin Pill can improve the efficacy of drug-coated balloon therapy alone in STEMI patients with postoperative qi deficiency and blood stasis, improve the patients’ Chinese medicine symptom scores and cardiac function indexes and reduce the inhibition of platelet aggregation, the mechanism of which may be related to the reduction of the level of inflammatory factors.